$SLNO News

Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition Deal

Soleno Therapeutics Inc (NASDAQ:SLNO): A Decent Value Play with Strong Health and Explosive Growth Potential

Wells Fargo Downgrades Soleno Therapeutics to Equal-Weight, Lowers Price Target to $53

Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers

HC Wainwright & Co. Downgrades Soleno Therapeutics to Neutral, Lowers Price Target to $53

TD Cowen Downgrades Soleno Therapeutics to Hold, Lowers Price Target to $53

Wolfe Research Downgrades Soleno Therapeutics to Peer Perform

Are Options Traders Betting on a Big Move in Soleno Therapeutics Stock?

Cantor Fitzgerald Downgrades Soleno Therapeutics to Neutral, Lowers Price Target to $53

Soleno Therapeutics shares are trading higher after the company announced that it will be acquired by Neurocrine Biosciences for $53 per share in cash.

Soleno Therapeutics shares are trading higher after the company announced that it will be acquired by Neurocrine Biosciences for $53 per share in cash.

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Oppenheimer Maintains Outperform on Soleno Therapeutics, Lowers Price Target to $80

Soleno Therapeutics Inc (NASDAQ:SLNO) Emerges as a Potential Fair-Value Opportunity

HC Wainwright & Co. Maintains Buy on Soleno Therapeutics, Lowers Price Target to $100

Wells Fargo Maintains Overweight on Soleno Therapeutics, Lowers Price Target to $110

Sector Update: Health Care Stocks Lower in Late Afternoon Trading

Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary

TD Cowen Maintains Buy on Soleno Therapeutics, Lowers Price Target to $85